drugset / Trial / NCT04721535
A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
RandomizedParallel-groupDouble-blindPrevention
Summary
To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.
Timeline
- Start
- 2021-06-07
- Primary completion
- 2021-09-23
- Completion
- 2021-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DWJ1248 | Unknown | 200 mg | Oral |